Abstract
Targeting mTOR by CCI-779 Lowers HIF Levels and Reduces Survival Advantage of VHL Renal Cell Cancers in Preclinical Studies
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have